Table.
Study characteristics
| LRC | HHS | WOSCOPS | AFCAPS/TexCAPS | |
|---|---|---|---|---|
| Drug (dose) | Colestyramine (24 g four times daily) | Gemfibrozil (600 mg twice daily) | Pravastatin (40 mg four times daily) | Lovastatin (20-40 mg four times daily) |
| Study duration (years) | 7 | 5 | 5 | 5 |
| No of subjects (intervention/control) | 1906/1900 | 2051/2030 | 3302/3293 | 3304/3301 |
| Mean age (years) | 48 | 47 | 55 | 58 |
| % of male subjects | 100 | 100 | 100 | 85 |
| Mean initial total cholesterol (mmol/l) | 7.5 | 7.4 | 7.0 | 5.7 |
| Mean reduction in total cholesterol (%) | 8.5† | 10‡ | 20‡ | 18§ |
LRC=Lipid Research Clinic primary prevention trial; HHS=Helsinki heart study; WOSCOPS=west of Scotland coronary prevention study; AFCAPS/TexCAPS=air force/Texas coronary prevention study.
*
Not intention to treat analysis. With intention to treat, the difference was 16% at five years.
†
At 7.4 years.
‡
At 5 years.
§
At 1 year.